➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Baxter
Moodys
Merck

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

TYSABRI Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for TYSABRI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Case Comprehensive Cancer CenterPhase 1/Phase 2
John LevinePhase 2
Dana-Farber Cancer InstitutePhase 2

See all TYSABRI clinical trials

Recent Litigation for TYSABRI

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Swiss Pharma International AG2016-04-18

See all TYSABRI litigation

Pharmacology for TYSABRI
Mechanism of ActionIntegrin Receptor Antagonists

Company Disclosures: US Patents for TYSABRI

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial University of Iowa Research Foundation (Oakdale, IA) 2009-12-01 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial University of Iowa Research Foundation (Iowa City, IA) 2005-01-30 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Fred Hutchinson Cancer Research Center (Seattle, WA) 2015-03-24 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for TYSABRI

These patents were identified by searching patent claims

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 27/2006 Austria   Start Trial PRODUCT NAME: NATALIZUMAB
27/2006 Austria   Start Trial PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
C20190004 00283 Estonia   Start Trial PRODUCT NAME: TISAGEENLEKLEUTSEEL;REG NO/DATE: EU/1/18/1297 27.08.2018
LUC00105 Luxembourg   Start Trial PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Johnson and Johnson
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.